Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
Findings from the Vax-On study show a favourable safety profile of mRNA-based COVID-19 vaccine in patients with solid tumours during active anticancer treatment
Evidence for efficacy is based on the results from the innovaTV 204 study
Findings from the PANAMA study (AIO KRK 0212)
Findings from the COSMIC-021 study